Skip to Main content Skip to Navigation
Journal articles

Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity

Jose Lopez-Atalaya 1, 2 Benoit Roussel 1, 2 Denis Levrat 3 Jerome Parcq 1, 2 Olivier Nicole 2 Yannick Hommet 1, 2 Karim Benchenane 1, 2 Hervé Castel 1, 2 Jérôme Leprince 4, 5 Denis To Van 6 Ronan Bureau 3 Sylvain Rault 3 Hubert Vaudry 4, 5 Karl-Uwe Petersen 7 Jana Sopkova-de Oliveira Santos 3 Carine Ali 1, 2 Denis Vivien 1, 2
1 Sérine protéases et physiopathologie de l'unité neurovasculaire
2 CI-NAPS - UMR 6232 - Centre-Imagerie, Neurosciences, et Application aux Pathologies
3 CERMN - Centre d'Etudes et de Recherche sur le Médicament de Normandie
4 Neuroendocrinologie cellulaire et moléculaire
5 IFRMP 23 - Institut Fédératif de Recherches Multidisciplinaires sur les Peptides
6 Biacore AB
7 PAION Deutschland GmbH
Abstract : Current thrombolytic therapy for acute ischemic stroke with tissue-type plasminogen activator (tPA) has clear global benefits. Nevertheless, evidences argue that in addition to its prohemorrhagic effect, tPA might enhance excitotoxic necrosis. In the brain parenchyma, tPA, by binding to and then cleaving the amino-terminal domain (ATD) of the NR1 subunit of N-methyl-D-aspartate (NMDA) glutamate receptors, increases calcium influx to toxic levels. We show here that tPA binds the ATD of the NR1 subunit by a two-sites system (K(D)=24 nmol/L). Although tenecteplase (TNK) and reteplase also display two-sites binding profiles, the catalytically inactive mutant TNKS478A displays a one-site binding profile and desmoteplase (DSPA), a kringle 2 (K2) domain-free plasminogen activator derived from vampire bat, does not interact with NR1. Moreover, we show that in contrast to tPA, DSPA does not promote excitotoxicity. These findings, together with three-dimensional (3D) modeling, show that a critical step for interaction of tPA with NR1 is the binding of its K2 domain, followed by the binding of its catalytic domain, which in turn cleaves the NR1 subunit at its ATD, leading to a subsequent potentiation of NMDA-induced calcium influx and neurotoxicity. This could help design safer new generation thrombolytic agents for stroke treatment.
Document type :
Journal articles
Complete list of metadata
https://hal-normandie-univ.archives-ouvertes.fr/hal-01972984
Contributor : Jérôme Leprince Connect in order to contact the contributor
Submitted on : Tuesday, January 8, 2019 - 9:53:35 AM
Last modification on : Tuesday, October 19, 2021 - 11:34:36 PM

Links full text

openaccess

Identifiers

Collections

COMUE-NORMANDIE | CNRS | UNIROUEN | UNICAEN | CERMN | CEA | FNCLCC | BECQUEREL | UNIV-PARIS5 | UNILEHAVRE | USPC | UNIV-PARIS

Citation

Jose Lopez-Atalaya, Benoit Roussel, Denis Levrat, Jerome Parcq, Olivier Nicole, et al.. Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity. Journal of Cerebral Blood Flow and Metabolism, Nature Publishing Group, 2008, 28 (6), pp.1212-1221. ⟨10.1038/jcbfm.2008.14⟩. ⟨hal-01972984⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

496